Revenue → Gross profit: $16.1BPharmaceutical → Revenue: $15.2BMedical devices → Revenue: $8.5BRevenue → Cost of revenue: $7.6BGross profit → Operating profit: $6.5BOncology → Pharmaceutical: $6.3BGross profit → SG&A: $5.9BOperating profit → Net profit: $5.5BImmunology → Pharmaceutical: $4.0BGross profit → R&D: $3.5BSurgery → Medical devices: $2.6BCardiovascular → Medical devices: $2.3BOrthopaedics → Medical devices: $2.3BNeuroscience → Pharmaceutical: $2.1BVision → Medical devices: $1.4BPulmonary → Pharmaceutical: $1.1BOperating profit → Tax: $1.0BOther pharma → Pharmaceutical: $0.9BInfectious diseases → Pharmaceutical: $0.8BGross profit → Other expense: $0.1BGross profit → Restructuring: $0.1BGross profit → Interest: $0.0BCardiovascular$2.3BCost of revenue$7.6B11% Y/YGross profit$16.1B3% Y/YImmunology$4.0BInfectious diseases$0.8BInterest$48MMedical devices$8.5B7% Y/YNet profit$5.5B18% Y/YNeuroscience$2.1BOncology$6.3BOperating profit$6.5B13% Y/YOrthopaedics$2.3BOther expense$107M-84% Y/YOther pharma$0.9BPharmaceutical$15.2B5% Y/YPulmonary$1.1BR&D$3.5B2% Y/YRestructuring$64MRevenue$23.7B6% Y/YSG&A$5.9B4% Y/YSurgery$2.6BTax$1.0B-10% Y/YVision$1.4BJohnson & Johnson Q2 FY25 Income Statementcreated with SankeyArt.com
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3
2025
Q1 Q2
Copy and edit diagram